

# Upcoming Internal and External Funding Opportunities in Cancer Research

Click here to view the opportunities online and bookmark the Siteman "Funding for Faculty" page.



Opportunities specific to early career applicants are noted in green below.

Deadline	Funding Opportunity	Sponsor	Max Amount and Period	RFP Snapshot Description	Eligibility Notes	Applicant Notes
Letter of Intent: June 11, 2024 - 10:59PM CST	<a href="#">AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants</a>	AACR-MPM Oncology	\$400,000 over 2 years	<i>This grant represents a joint effort to stimulate "high-risk, high-reward" research from early- to mid-career investigators. The proposed research must represent a highly innovative approach to a major problem or challenge in cancer research. This grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that might not be funded through conventional channels. It is expected that these grants will catalyze significant scientific discoveries that will advance our understanding of cancer and have a potentially transformative impact on future clinical practice.</i>	Applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. Applicants must be at the rank of Assistant Professor or Associate Professor. Applicants also must be AACR Active members in good standing.	<u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.
June 13, 2024 - 7PM CST <b>EARLY CAREER SPECIFIC OPPORTUNITY</b>	<a href="#">ALSF A Award Grant</a>	Alex's Lemonade Stand Foundation	\$800,000 over 4 years	<i>The purpose of this program is to advance ALSF's mission to find cures and better treatments for childhood cancers by providing support to scientists focused on pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of a future commitment to pediatric cancer investigation as well as institutional support for the career development of the investigator are critical components of a successful application. A mentor is required, and a career development plan must be included.</i>	Applicants must have an MD, PhD or MD/PhD (DO, MBBS or equivalent) and be within ten years of their terminal degree and five years of their first faculty appointment as an Assistant Professor at the time that their application is submitted. More senior Assistant Professors, as well as Associate and Full Professors, are ineligible. If still at the Instructor level, the applicant must have a firm commitment from the Department Chair/Division Chief at the time of grant submission for an Assistant Professor position within one year of receiving the award. A minimum of 75% of the applicant's time must be allocated as non-clinical protected time for all research activities. A mentor must be identified from the applicant's home institution. Applicants may not be the PI of a K99/R00 or other nationally-competitive award such as an R01 or equivalent, P, or U award. Applicants cannot have 2 R21s or 2 R03s at any time before the award.	<u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.
June 14, 2024 - 10:59PM CST	<a href="#">2024 Research Grants in Cancer Prevention and Early-Detection</a>	PreventCancer	\$100,000 over 2 years	<i>Research projects will be aimed at reducing the frequency of neoplasms including but not limited to brain, bladder, breast, colon and rectum, endometrium, head and neck, kidney, liver, lung, ovary, pancreas, prostate, skin (including melanoma), stomach as well as HPV-related cancers and hematologic malignancies.</i>	Eligible applications must be original and clearly describe pre-clinical, translational, clinical or innovative research projects in the field of cancer prevention or early detection. Projects that evaluate the potential for dissemination and implementation into clinical and community health settings are eligible.	<u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.

<p>June 15, 2024 - 11:59PM CST</p> <p><b>EARLY CAREER SPECIFIC OPPORTUNITY</b></p>	<p><a href="#">AST Research Network Transition to Independence Grants</a></p>	<p>American Society of Transplantation Research Network</p>	<p>\$115,000 over 2 years</p>	<p><i>The purpose of the AST Research Network Transition to Independence Research Grants is to promote the careers of academic investigators whose development of an independent research program is focused on the field of basic science, translational and clinical investigation in solid organ transplantation. The grants are intended to provide support for the investigator's transition to an R-series or equivalent grant.</i></p>	<p>Applicants must have a doctoral degree (MD, DO, PhD, DVM, PharmD, or equivalent), must have completed post-graduate training, and must have obtained an institutional commitment that is sufficient to conduct research and allow for long-term success. The applicants must be active members of the AST or have submitted a completed membership application by the deadline. Applicants may hold a career development grant (e.g. K grant), but may NOT be the PI on a previous or current NIH grant to perform independent research. Applicants may apply for an AST grant at the same time as applying for an NIH R01, P01, or comparable award. See RFA for more details.</p>	<p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.</p>
<p>June 17, 2024 - 10:59PM CST</p> <p><b>EARLY CAREER SPECIFIC OPPORTUNITY</b></p>	<p><a href="#">Career Development Award (CDA)</a></p>	<p>ASCO, Conquer Cancer</p>	<p>\$200,000 over 3 years</p>	<p><i>The Career Development Award (CDA) provides research funding to clinical investigators, who have received their initial faculty appointment, as they work to establish an independent clinical cancer research program. This is a mentored award and the research project is conducted under the guidance of a scientific mentor. The research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects.</i></p>	<p>Applicants must be an MD, DO, or international equivalent working in any country. They must be in the first to fourth year of a full-time primary faculty appointment in a clinical department. Applicants must have completed productive postdoctoral research and demonstrated the ability to undertake independent investigator-initiated clinical research. Applicants must be an ASCO member or submitted a membership application and be able to commit at least 50% of full-time effort in research. Applicants must have a mentor from the sponsoring institution. Applicants may not hold other concurrent career development awards from private foundations. See RFA for list.</p>	<p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.</p>
<p>June 30, 2024 - 10:59PM CST</p> <p><b>EARLY CAREER SPECIFIC OPPORTUNITY</b></p>	<p><b>NEW:</b> <a href="#">Siteman Trainee Travel Awards</a></p>	<p>Siteman Cancer Center</p>	<p>\$1,500</p>	<p><i>The Siteman Trainee Travel Award supports scholars in career development related to cancer research or cancer health disparities research by providing reimbursement (i.e. registration, airfare, hotel, etc.) to present research at conferences and/or attend workshops/trainings. Scholars who are Underrepresented in Medicine (URiM) and/or women are strongly encouraged to apply.</i></p>	<p>Trainee must be affiliated with Siteman Cancer Center, Washington University, BJC, Children's Hospital, SLU, or University of Missouri. All cancer related research and cancer disparities research trainees encouraged to apply. Priority given to NCI affiliated trainees. Must be a pre-doctoral trainee (doctoral student), postdoctoral trainee, research fellow, or early career faculty (instructor or assistant professor who has not yet held an R01 award). Conference location must be within the domestic USA; includes Canada, Mexico, and US Territories. This award may be used as a supplement to other scholarships, but may not be used to duplicate other resources.</p>	<p>N/A</p>
<p>July 1, 2024 - Noon CST</p> <p><b>EARLY CAREER SPECIFIC OPPORTUNITY</b></p>	<p><a href="#">AACR-Novocure Career Development Award for Cancer Research</a></p>	<p>AACR</p>	<p>\$300,000 over 3 years</p>	<p><i>This grant represents a joint effort to promote and support early-career investigators who are conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage early-career investigators to enter the TTFields research field. The In vitro system (which will be provided by Novocure, if needed), must be included in the experimental design.</i></p>	<p>Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Applicants must hold a faculty position with the title of Instructor, Research Assistant Professor, or Assistant Professor. They must have received their first faculty position with the past six years, i.e. must have begun their appointment on December 1, 2018 or later.</p>	<p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.</p>



<p>July 1, 2024 - Noon CST</p> <p><b>EARLY CAREER SPECIFIC OPPORTUNITY</b></p>	<p><a href="#">AACR-Novocure Cancer Research Grants</a></p>	<p>AACR</p>	<p>\$350,000 over 3 years</p>	<p><i>This grant represents a joint effort to promote and support independent investigators who are currently conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage independent investigators to enter the TTFields research field. The Inovitro® system (which will be provided by Novocure, if needed), must be included in the experimental design.</i></p>	<p>Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Current AACR Grantees may apply if their current grant ends before the start of the grant term of this funding opportunity i.e., December 1, 2024, and must be up to date with all reporting requirements to be considered eligible. Applicants must also be AACR Active members in good standing.</p>	<p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.</p>
<p>July 8, 2024 - 3PM CST</p>	<p><a href="#">Damon Runyon-Rachleff Innovation Award Stage 1</a></p>	<p>Damon Runyon Cancer Research Foundation</p>	<p>\$400,000 over 2 years</p>	<p><i>The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.</i></p>	<p>Applicants (including non-U.S. citizens) must be conducting independent research at a U.S. research institution. The applicant must have received an MD, DO, PhD, or MD/PhD degree(s) from an accredited institution. Basic and translational/clinical projects will be considered. Applications will be accepted from all scientific disciplines provided that the proposed research meets the selection criteria.</p>	<p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.</p>
<p><u>Letter of Intent:</u> July 9, 2024 - Noon CST</p> <p><b>EARLY CAREER SPECIFIC OPPORTUNITY</b></p>	<p><a href="#">Fanconi Cancer Foundation-AACR NextGen Grant for Transformative Cancer Research</a></p>	<p>AACR</p>	<p>\$450,000 over 3 years</p>	<p><i>This grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that may not be funded through conventional channels. It is expected that this grant will catalyze significant scientific discoveries and help talented young investigators gain scientific independence. Fanconi anemia (FA) is a rare genetic disease caused by loss-of-function mutations in any one of 22 FA genes, which are integral to the FA/BRCA DNA repair pathway and include the breast cancer susceptibility genes BRCA1 and BRCA2. The disease is marked by congenital abnormalities, bone marrow failure, and a high risk of solid tumors and leukemia. Individuals with FA have a hundreds- to thousands-fold increased risk of developing squamous cell cancers of the head and neck, esophagus, and anogenital regions, in addition to an elevated risk for other solid tumors.</i></p>	<p>Applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. Applicants must currently hold a tenure-eligible appointment at the rank of Assistant Professor, and they must have begun that appointment on December 1, 2021 or later. Applicants also must be AACR Active members in good standing.</p>	<p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.</p>
<p>July 15, 2024 - 10:59PM CST</p>	<p><a href="#">Hyundai Hope on Wheels Pediatric Cancer Survivorship Collaboration Award</a></p>	<p>Hyundai Hope on Wheels</p>	<p>\$1M over 3 years</p>	<p><i>The Survivorship Collaboration Award was developed to provide funding for collaborative research projects focused on pediatric cancer survivorship. The ultimate long-term goal is to improve the quality of life of pediatric cancer survivors. Survivorship Collaboration Awards should be translational in nature, with a clear path to directly impacting patients. Proposals will be judged based on innovation, impact, and clear, measurable and demonstrated outcomes by the end of the three-year period of support.</i></p>	<p>Eligible applicants for this grant must have a doctoral degree (MD, DO, PhD), a solid track record of involvement in pediatric cancer survivorship, and must be able to commit at least 10% effort to the project. A key component of the Hyundai Survivorship Grant is the requirement for collaboration by two or more institutions, each of which must make substantial contributions to a shared project.</p>	<p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.</p>
<p><u>Letter of Intent:</u> August 1, 2024 - 10:59PM CST</p>	<p><a href="#">NEW: ACS Professor Awards</a></p>	<p>American Cancer Society</p>	<p>\$400,000 over 5 years</p>	<p><i>ACS Professor awards are primarily honorific awards for individuals who have made seminal contributions in cancer research. Applicants must be at the rank of full professor and have made, and will likely continue to make, impactful contributions to change the direction of cancer research. These notable cancer research achievements could have been fundamental, preclinical, clinical, psychosocial, behavioral, health policy and/or epidemiologic in focus. Commitment and success in scientific mentoring and leadership as well as community engagement are also carefully considered.</i></p>	<p>Applicants must have obtained the rank of full professor and must be ready to be spokespeople for ACS and for cancer research in general.</p>	<p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.</p>

August 5, 2024 - 5PM CST	<a href="#">NEW: Multi-sectoral Preventive Interventions that Address Social Determinants of Health in Populations that Experience Health Disparities (UG3/UH3, Clinical Trial Required)</a>	NIH/NCI	\$4.75M over 7 years UG3 Phase - 2 years UH3 Phase - 5 years	<i>The purpose of this NOFO is to support projects to test prospective multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. This opportunity solicits bi-phasic research projects proposed in UG3/UH3 Phased Innovation Awards Cooperative Agreement applications. Funding for the UG3 phase (phase I) will be used to demonstrate sufficient preparation, feasibility and capacity to meet foundational milestone targets specific to the work proposed. A UG3 project that meets its milestones will be administratively considered by NIH and prioritized for transition to the UH3 award (phase II). Applicants responding to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases.</i>	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	N/A
August 31, 2024 - 5PM CST <b>EARLY CAREER SPECIFIC OPPORTUNITY</b>	<a href="#">NEW: Elsa U. Pardee Foundation Grants</a>	Elsa U. Pardee Foundation	No Limit for 1 Year <i>Budget must be reasonably supported by scope of project</i>	<i>This grant is meant to support investigators in the US proposing research directed toward identifying new treatments or cures for cancer. The Foundation funds projects for a one-year period which will allow the establishment of capabilities of new cancer researchers or new cancer approaches by established cancer researchers. It is anticipated that this early-stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.</i>	Priority is given to researchers at non-profit institutions in the United States who are new to the field of cancer research, or to established research investigators examining new approaches to cancer cure. Post-docs who are on the tenure track and have a tenured mentor are eligible.	<b>Application Assistance:</b> Washington University faculty may reach out to Danny Jaschek in Medical Corporate and Foundation Relations at <a href="mailto:daniel.jaschek@wustl.edu">daniel.jaschek@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.
August 31, 2024 - 10:59PM CST	<a href="#">NEW: ACS Extramural Discovery Science Accelerator Award</a>	American Cancer Society	\$75,000 for 1 year	<i>The intent of the Extramural Discovery Science (EDS) Accelerator Award is to support the commercialization of an ongoing cancer research project and to validate and de-risk technologies. Proposals should address key experiment(s) required to move findings toward commercialization that do not easily fit into traditional grant funding mechanisms. This mechanism is not designed to initiate new projects or develop new directions for an ongoing project. The proposal should be commercially driven with the PI having a plan to license the technology, either to an established company or a start-up if the experiment(s) are successful.</i>	Applicants must be current or former ACS awardees (including IRG pilot grant awardees), or former ACS postdoctoral fellows. Applicants may be at any career stage, provided they have a full-time faculty appointment. Applicants must be motivated to commercialize their technology.	<b>Application Assistance:</b> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing the proposal.

**Internal Grant Resources (≤\$25) with Rolling Deadlines**

Sponsor	Website	Notes
SCC BQSR Biostatistics and Qualitative Research Shared Resource	<a href="#">Grant Preparation Support - Free for SCC Members</a>	N/A
WUSTL CDD Center for Drug Discovery	<a href="#">CDD Match Grants</a>	Rolling Deadlines
WUSTL ICTS Institute of Clinical and Translational Sciences	<a href="#">Innovation Awards</a>	Rolling Deadlines
WUSTL ICTS and Siteman Cancer Center	<a href="#">Just-in-Time (JIT) Core Usage Funding Program</a>	Rolling Deadlines; Siteman Cancer Center will co-sponsor cancer-focused proposals.

**OTHER FUNDING OPPORTUNITY QUICK LINKS**

Be sure to check the websites below regularly for ongoing NATIONAL funding opportunities.

<b>NEW: WUSTL Funding Database</b>	<a href="https://research.wustl.edu/funding/finding-funding/funding-opportunity-database/">https://research.wustl.edu/funding/finding-funding/funding-opportunity-database/</a>
WUSTL CDI	<a href="https://implementationresearch.wustl.edu/support-your-research/funding-opportunities-2/">https://implementationresearch.wustl.edu/support-your-research/funding-opportunities-2/</a>
DOD	<a href="https://cdmrp.health.mil/funding/">https://cdmrp.health.mil/funding/</a>
NCI	<a href="https://www.cancer.gov/grants-training/grants-funding/funding-opportunities">https://www.cancer.gov/grants-training/grants-funding/funding-opportunities</a>
NIH	<a href="https://grants.nih.gov/funding/index.htm">https://grants.nih.gov/funding/index.htm</a>

This newsletter is not fully inclusive of all available cancer-related funding.  
Please be sure to consult other sources to learn of other opportunities not listed above.

[Click to view these opportunities in a web browser and bookmark the Siteman “Funding for Faculty” page.](#)